Aurinia Pharmaceuticals Inc. (AUPH): Operating Income
$104.91M
Year ended 2025-12-31
$150.75M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $104.91M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$4.69M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$91.69M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$111.47M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$180.74M | n/m | 2024-02-15, From 2021-01-01 |
| 2020-12-31 | -$104.29M | n/m | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$90.94M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$55.24M | n/a | 2021-02-24, From 2018-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | 2025-12-31 | $104.91M | n/m |
| Summit Therapeutics Inc. (SMMT) | 2024-12-31 | -$226.00M | n/m |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $77.22M | n/m |
| Cryoport, Inc. (CYRX) | 2025-12-31 | -$36.81M | n/m |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | -$303.63M | n/m |
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | -$315.47M | n/m |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | -$225.68M | n/m |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | -$215.27M | n/m |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | -$209.56M | n/m |
Compare AUPH, SMMT, KNSA, CYRX side by side · Screen every company in Pharmaceutical Preparations ↗